Johnson & Johnson
South Africa signs J&J vaccine deal, eases restrictions
South Africa has signed an agreement with Johnson & Johnson to secure 11 million COVID-19 vaccine doses and will ease restrictions due to a decline in new cases, President Cyril Ramaphosa said on Sunday. South Africa has been the hardest-hit on the continent by the pandemic, recording almost half of the COVID-19 deaths and more than a third of reported infections. But daily cases have fallen below 2,000, from a peak above 20,000 last month during a second wave of infections. Ramaphosa said in a televised address that 2.8 million of the J&J doses would be delivered in the second quarter, with the rest spread throughout the year. South Africa started administering the single-dose J&J vaccine this month in a research study targeting healthcare workers but has not yet rolled out sh...
Nigeria expects 41 million coronavirus vaccine doses from African Union
Nigeria expects to receive 41 million Covid-19 vaccine doses from the African Union, the head of the country’s primary healthcare agency said on Monday, while the health minister said vaccines from Russia and India were being considered. Authorities in Africa’s most populous country, which has 200 million people, plan to inoculate 40% of the population this year and another 30% in 2022. The African Union initially secured 270 million Covid-19 vaccine doses from manufacturers for member states. Last week it was announced that the bloc would receive another 400 million doses of the AstraZeneca vaccine. Faisal Shuaib, who heads the National Primary Health Care Development Agency, said Nigeria’s previous request for 10 million doses through the AU had been increased four-fold. “We have applied...
Europe to pay less than US for Pfizer COVID-19 vaccine
The European Union has struck a deal to initially pay less for Pfizer’s COVID-19 vaccine candidate than the United States, an EU official told Reuters News Agency as the bloc announced on Wednesday it had secured an agreement for up to 300 million doses. The experimental drug, developed in conjunction with Germany’s BioNTech, is the frontrunner in a global race to produce a vaccine, with interim data released on Monday showing it was more than 90 percent effective at protecting people from COVID-19 in a large-scale clinical trial. Under the EU deal, 27 European countries could buy 200 million doses, and have an option to buy another 100 million. The bloc will pay less than $19.50 per jab, a senior EU official involved in talks with vaccine makers told Reuters, adding that partly reflected ...
